SCHEMBL23289657

SCHEMBL23289657

CNCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
KDM4A O75164 1/20 0.37
KDM4C Q9H3R0 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
KDM4E B2RXH2 6/20 0.35
EGLN1 Q9GZT9 3/20 0.35
KDM5C P41229 2/20 0.35
PHF8 Q9UPP1 2/20 0.35
KDM2A Q9Y2K7 2/20 0.35
TSHR P16473 1/20 0.35
ALDH1A1 P00352 3/20 0.34
BLM P54132 1/20 0.34
PMP22 Q01453 1/20 0.34
HSD17B10 Q99714 1/20 0.34
LMNA P02545 3/20 0.33
FFAR3 O14843 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24513773 1.00 MEN1 (0.39) MEN1KMT2AKDM4AKDM4CSMN1; SMN2
SCHEMBL2720582 1.00 MEN1 (0.39) MEN1KMT2AKDM4AKDM4CSMN1; SMN2
SCHEMBL26900583 1.00 MEN1 (0.39) MEN1KMT2AKDM4AKDM4CSMN1; SMN2
SCHEMBL12092144 1.00 MEN1 (0.39) MEN1KMT2AKDM4AKDM4CSMN1; SMN2
SCHEMBL13213153 1.00 MEN1 (0.39) MEN1KMT2AKDM4AKDM4CSMN1; SMN2
SCHEMBL25413833 1.00 MEN1 (0.39) MEN1KMT2AKDM4AKDM4CSMN1; SMN2
SCHEMBL932529 1.00 MEN1 (0.39) MEN1KMT2AKDM4AKDM4CSMN1; SMN2
SCHEMBL17801933 0.98 MEN1 (0.38) MEN1KMT2AKDM4AKDM4CSMN1; SMN2
SCHEMBL16132772 0.98 KDM4A (0.38) MEN1KMT2AKDM4AKDM4CSMN1; SMN2
SCHEMBL26383116 0.89 BLM (0.48) MEN1KMT2AKDM4AKDM4CSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11654199-B2 Thienoazepine immunoconjugates, and uses thereof BOLT BIOTHERAPEUTICS, INC. (US) 2023-05-23 US disclosed
US-20210128744-A1 THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF BOLT BIOTHERAPEUTICS, INC. (US) 2021-05-06 US disclosed
WO-2021081402-A1 MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF BOLT BIOTHERAPEUTICS, INC. (US) 2021-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11654199-B2 Thienoazepine immunoconjugates, and uses thereof ICOS, CYP3A5, TPH1 MEN1 1637/4885KMT2A 994/4885KDM4A 433/4885
US-20210128744-A1 THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF ICOS, CYP3A5, TPH1 MEN1 1637/4885KMT2A 994/4885KDM4A 433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.